47 results on '"Murthy, Neil"'
Search Results
2. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older--United States, 2024
- Author
-
Murthy, Neil, Wodi, A. Patricia, McNally, Veronica V., Daley, Matthew F., and Cineas, Sybil
- Subjects
Pfizer Inc. ,Vaccination ,Health care industry ,Adults ,DPT vaccine ,Pharmaceutical industry ,Health care industry ,Health ,Abrysvo (Vaccine) - Abstract
At its October 2023 meeting, the Advisory Committee on Immunization Practices * (ACIP) approved the Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, 2024. The adult [...]
- Published
- 2024
3. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger--United States, 2024
- Author
-
Wodi, A. Patricia, Murthy, Neil, McNally, Veronica V., Daley, Matthew F., and Cineas, Sybil
- Subjects
Pfizer Inc. ,Vaccination ,Tetanus antitoxin ,Health care industry ,DPT vaccine ,Pharmaceutical industry ,Health care industry ,Health ,Menactra (Vaccine) ,Abrysvo (Vaccine) - Abstract
At its October 2023 meeting, the Advisory Committee on Immunization Practices * (ACIP) approved the Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024. [...]
- Published
- 2024
4. Disparities in First Dose COVID-19 Vaccination Coverage among Children 5-11 Years of Age, United States
- Author
-
Murthy, Neil Chandra, Zell, Elizabeth, Fast, Hannah E., Murthy, Bhavini Patel, Meng, Lu, Saelee, Ryan, Vogt, Tara, Chatham-Stephens, Kevin, Ottis, Christina, Shaw, Lauren, Gibbs-Scharf, Lynn, Harris, LaTreace, and Chorba, Terence
- Subjects
Vaccination -- Distribution -- Demographic aspects ,Health care disparities -- Research ,Pediatric research ,Company distribution practices ,Health - Abstract
Although more common among adults, severe coronavirus disease (COVID-19) and hospitalization can occur in children. Among >8,300 hospitalized children 5-11 years of age, 1/3 required intensive care (1,2). Children can [...]
- Published
- 2022
- Full Text
- View/download PDF
5. COVID-19 Vaccination Coverage and Demographic Characteristics of Infants and Children Aged 6 Months-4 Years--United States, June 20-December 31, 2022
- Author
-
Murthy, Bhavini Patel, Fast, Hannah E., Zell, Elizabeth, Murthy, Neil, Meng, Lu, Shaw, Lauren, Vogt, Tara, Chatham-Stephens, Kevin, Santibanez, Tammy A., Gibbs-Scharf, Lynn, and Harris, LaTreace Q.
- Subjects
United States. Census Bureau ,Pfizer Inc. ,Vaccination ,Evidence-based medicine ,Pharmaceutical industry ,Health - Abstract
Although severe COVID-19 illness and hospitalization are more common among older adults, children can also be affected (1). More than 3 million cases of COVID-19 had been reported among infants [...]
- Published
- 2023
6. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older--United States, 2023
- Author
-
Murthy, Neil, Wodi, A. Patricia, McNally, Veronica, Cineas, Sybil, and Ault, Kevin
- Subjects
Vaccination ,Health care industry ,Adults ,Health care industry ,Health - Abstract
At its October 2022 meeting, the Advisory Committee on Immunization Practices * (ACIP) approved the Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, 2023. The 2023 [...]
- Published
- 2023
7. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger--United States, 2023
- Author
-
Wodi, A. Patricia, Murthy, Neil, McNally, Veronica, Cineas, Sybil, and Ault, Kevin
- Subjects
Vaccination ,Health care industry ,Health care industry ,Health - Abstract
At its October 2022 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2023. The [...]
- Published
- 2023
8. Recommended Adult Immunization Schedule, United States, 2024.
- Author
-
Murthy, Neil, Wodi, A. Patricia, McNally, Veronica V., Daley, Matthew F., and Cineas, Sybil
- Subjects
- *
IMMUNIZATION , *ADULTS , *SCHEDULING , *VACCINATION - Abstract
This article provides immunization recommendations from the Advisory Committee on Immunization Practices (ACIP) for adults aged 19 years or older. The purpose of the immunization schedule is to consolidate and summarize updates to ACIP recommendations on vaccination of adults and to assist providers in implementing current ACIP recommendations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Vaccination Coverage Among Children Aged 2 Years — U.S. Affiliated Pacific Islands, April–October, 2016
- Author
-
Tippins, Ashley, Murthy, Neil, Meghani, Mehreen, Solsman, Amy, Apaisam, Carter, Basilius, Merlyn, Eckert, Maribeth, Judicpa, Peter, Masunu, Yolanda, Pistotnik, Kelsey, Pedro, Daisy, Sasamoto, Jeremy, and Underwood, J. Michael
- Published
- 2018
10. Absence of Asymptomatic Mumps Virus Shedding Among Vaccinated College Students During a Mumps Outbreak — Washington, February–June 2017
- Author
-
Bonwitt, Jesse, Kawakami, Vance, Wharton, Adam, Burke, Rachel M., Murthy, Neil, Lee, Adria, Dell, BreeAnna, Kay, Meagan, Duchin, Jeff, Hickman, Carole, McNall, Rebecca J., Rota, Paul A., Patel, Manisha, Lindquist, Scott, DeBolt, Chas, and Routh, Janell
- Published
- 2017
11. Progress in Childhood Vaccination Data in Immunization Information Systems — United States, 2013–2016
- Author
-
Murthy, Neil, Rodgers, Loren, Pabst, Laura, Fiebelkorn, Amy Parker, and Ng, Terence
- Published
- 2017
12. The 6 E Framework of Public Health Preparedness for Mass Gatherings—Lessons Learned From Super Bowl LIII, Fulton County, Georgia, 2019
- Author
-
Murthy, Neil C., Holland, David P., Chamberlain, Allison T., Smith, Sasha, Callahan, John, and Smith, Wendy
- Published
- 2020
- Full Text
- View/download PDF
13. Booster COVID-19 Vaccinations Among Persons Aged [greater than or equal to]5 Years and Second Booster COVID-19 Vaccinations Among Persons Aged [greater than or equal to]50 Years--United States, August 13, 2021-August 5, 2022
- Author
-
Fast, Hannah E., Murthy, Bhavini Patel, Zell, Elizabeth, Meng, Lu, Murthy, Neil, Saelee, Ryan, Lu, Peng-jun, Kang, Yoonjae, Shaw, Lauren, Gibbs-Scharf, Lynn, and Harris, LaTreace
- Subjects
Pfizer Inc. ,Vaccination ,Health - Abstract
COVID-19 vaccine booster doses provide enhanced protection against SARS-CoV-2 infection, emergency department visits, hospitalization, and death (1-3). As of May 19, 2022, all fully vaccinated persons aged [greater than or [...]
- Published
- 2022
14. Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties--United States, December 14, 2020-January 31, 2022
- Author
-
Saelee, Ryan, Zell, Elizabeth, Murthy, Bhavini Patel, Castro-Roman, Patricia, Fast, Hannah, Meng, Lu, Shaw, Lauren, Gibbs-Scharf, Lynn, Chorba, Terence, Harris, LaTreace Q., and Murthy, Neil
- Subjects
Pfizer Inc. ,Vaccination ,Pharmaceutical industry ,Health - Abstract
Higher COVID-19 incidence and mortality rates in rural than in urban areas are well documented (1). These disparities persisted during the B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant surges during late [...]
- Published
- 2022
15. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger--United States, 2022
- Author
-
Wodi, A. Patricia, Murthy, Neil, Bernstein, Henry, McNally, Veronica, Cineas, Sybil, and Ault, Kevin
- Subjects
Immunization ,Health care industry ,Vaccines ,Health care industry ,Health - Abstract
At its November 2021 meeting, the Advisory Committee on Immunization Practices * ([section]) (ACIP) approved the Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger--United States, 2022. [...]
- Published
- 2022
16. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older--United States, 2022
- Author
-
Murthy, Neil, Wodi, A. Patricia, Bernstein, Henry, McNally, Veronica, Cineas, Sybil, and Ault, Kevin
- Subjects
Immunization ,Health care industry ,Adults ,Vaccines ,Health care industry ,Health - Abstract
At its November 2021 meeting, the Advisory Committee on Immunization Practices * (ACIP) approved the Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, 2022. The 2022 [...]
- Published
- 2022
17. Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged [greater than or equal to] 65 Years--United States, August 13, 2021-November 19, 2021
- Author
-
Fast, Hannah E., Zell, Elizabeth, Murthy, Bhavini Patel, Murthy, Neil, Meng, Lu, Scharf, Lynn Gibbs, Black, Carla L., Shaw, Lauren, Chorba, Terence, and Harris, LaTreace Q.
- Subjects
United States. Department of Health and Human Services ,Pfizer Inc. ,Vaccination -- Health aspects ,Adults -- Health aspects ,Pharmaceutical industry -- Health aspects ,Health - Abstract
On December 10, 2021, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). Vaccination against SARS-CoV-2 (the virus that causes COVID-19) is highly effective at [...]
- Published
- 2021
18. COVID-19 Vaccination Coverage Among Adolescents Aged 12-17 Years--United States, December 14, 2020-July 31, 2021
- Author
-
Murthy, Bhavini Patel, Zell, Elizabeth, Saelee, Ryan, Murthy, Neil, Meng, Lu, Meador, Seth, Reed, Kirsten, Shaw, Lauren, Gibbs-Scharf, Lynn, McNaghten, A.D., Patel, Anita, Stokley, Shannon, Flores, Stephen, Yoder, Jonathan S., Black, Carla L., and Harris, LaTreace Q.
- Subjects
United States. Food and Drug Administration -- Reports ,Johnson & Johnson -- Reports ,Pfizer Inc. -- Reports ,Vaccination -- Reports ,Teenagers -- Reports ,Youth -- Reports ,Evidence-based medicine -- Reports ,Pharmaceutical industry -- Reports ,Health - Abstract
On August 27, 2021, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). Although severe COVID-19 illness and hospitalization are more common among adults, these [...]
- Published
- 2021
19. Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties--United States, December 14, 2020-April 10, 2021
- Author
-
Murthy, Bhavini Patel, Sterrett, Natalie, Weller, Daniel, Zell, Elizabeth, Reynolds, Laura, Toblin, Robin L., Murthy, Neil, Kriss, Jennifer, Rose, Charles, Cadwell, Betsy, Wang, Alice, Ritchey, Matthew D., Gibbs-Scharf, Lynn, Qualters, Judith R., Shaw, Lauren, Brookmeyer, Kathryn A., Clayton, Heather, Eke, Paul, Adams, Laura, Zajac, Julie, Patel, Anita, Fox, Kimberley, Williams, Charnetta, Stokley, Shannon, Flores, Stephen, Barbour, Kamil E., and Harris, LaTreace Q.
- Subjects
Johnson & Johnson ,Vaccination ,Medically uninsured persons ,Pharmaceutical industry ,Health - Abstract
On May 18, 2021, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). Approximately 60 million persons in the United States live in rural counties, [...]
- Published
- 2021
20. Minority Health Social Vulnerability Index and COVID-19 vaccination coverage — The United States, December 14, 2020–January 31, 2022.
- Author
-
Saelee, Ryan, Chandra Murthy, Neil, Patel Murthy, Bhavini, Zell, Elizabeth, Shaw, Lauren, Gibbs-Scharf, Lynn, Harris, LaTreace, and Shaw, Kate M.
- Subjects
- *
VACCINATION coverage , *COVID-19 vaccines , *HEALTH of minorities , *BOOSTER vaccines , *CHILDREN with disabilities , *VACCINATION , *PER capita - Abstract
In 2021, HHS Office of Minority Health and CDC developed a composite measure of social vulnerability called the Minority Health Social Vulnerability Index (MHSVI) to assess the needs of communities most vulnerable to COVID-19. The MHSVI extends the CDC Social Vulnerability Index with two new themes on healthcare access and medical vulnerability. This analysis examines COVID-19 vaccination coverage by social vulnerability using the MHSVI. County-level COVID-19 vaccine administration data among persons aged ≥18 years reported to CDC from 12/14/20 to 01/31/22 were analyzed. U.S. counties from 50 states and DC were categorized into tertiles of vulnerability (low, moderate, and high) for the composite MHSVI measure and each of the 34 indicators. Vaccination coverage (≥1 dose, primary series completion, and receipt of a booster dose) was calculated by tertiles for the composite MHSVI measure and each indicator. Counties with lower per capita income, higher proportion of individuals with no high school diploma, living below poverty, ≥65 years of age, with a disability, and in mobile homes had lower vaccination uptake. However, counties with larger proportions of racial/ethnic minorities and individuals speaking English less than "very well" had higher coverage. Counties with fewer primary care physicians and greater medical vulnerabilities had lower ≥ 1 dose vaccination coverage. Furthermore, counties of high vulnerability had lower primary series completion and receipt of a booster dose. There were no clear patterns in COVID-19 vaccination coverage by tertiles for the composite measure. Results from the new components in the MHSVI identify needs to prioritize persons in counties with greater medical vulnerabilities and limited access to health care, who are at greater risk for adverse COVID-19 outcomes. Findings suggest that using a composite measure to characterize social vulnerability might mask disparities in COVID-19 vaccination uptake that would have otherwise been observed using specific indicators. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Recommended Adult Immunization Schedule, United States, 2023.
- Author
-
Murthy, Neil, Wodi, A. Patricia, Cineas, Sybil, Ault, Kevin A., Lee, Grace M., Wharton, Melinda, Bahta, Lynn, Bell, Beth P., Brooks, Oliver, Chen, Wilbur H., Daley, Matthew F., Kotton, Camille Nelson, Loehr, Jamie, Long, Sarah S., McNally, Veronica V., Poehling, Katherine A., Sánchez, Pablo J., Shah, Nirav D., Talbot, Helen Keipp, and McNally, Veronica
- Subjects
- *
IMMUNIZATION , *ADULTS , *SCHEDULING , *VACCINATION - Abstract
This article provides immunization recommendations from the Advisory Committee on Immunization Practices (ACIP) for adults aged 19 years or older. The purpose of the immunization schedule is to consolidate and summarize updates to ACIP recommendations on vaccination of adults and to assist providers in implementing current ACIP recommendations. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. COVID-19 Vaccination Coverage and Demographic Characteristics of Infants and Children Aged 6 Months--4 Years -- United States, June 20--December 31, 2022.
- Author
-
Patel Murthy, Bhavini, Fast, Hannah E., Zell, Elizabeth, Murthy, Neil, Lu Meng, Shaw, Lauren, Vogt, Tara, Chatham-Stephens, Kevin, Santibanez, Tammy A., Gibbs-Scharf, Lynn, and Harris, LaTreace Q.
- Subjects
COVID-19 vaccines ,DISEASES ,IMMUNIZATION ,HOSPITAL care ,POPULATION - Abstract
The article presents the discussion on COVID-19 illness and hospitalization being more common among older adults. Topics include CDC by jurisdictions, pharmacies, and federal entities through immunization information systems (IISs); and tests for statistical significance being notconducted due to the data reflecting the U.S. population not based on population samples.
- Published
- 2023
- Full Text
- View/download PDF
23. COVID-19 Vaccine Initiation and Dose Completion During the SARS-CoV-2 Delta Variant Surge in the United States, December 2020–October 2021.
- Author
-
Murthy, Neil, Saelee, Ryan, Patel Murthy, Bhavini, Meng, Lu, Shaw, Lauren, Gibbs-Scharf, Lynn, Harris, LaTreace, Chorba, Terence, and Zell, Elizabeth
- Subjects
- *
GENETIC mutation , *COVID-19 , *COVID-19 vaccines , *TREATMENT effectiveness , *HOSPITAL care , *DESCRIPTIVE statistics - Abstract
Objectives: In summer 2021, the number of COVID-19–associated hospitalizations in the United States increased with the surge of the SARS-CoV-2 Delta variant. We assessed how COVID-19 vaccine initiation and dose completion changed during the Delta variant surge, based on jurisdictional vaccination coverage before the surge. Methods: We analyzed COVID-19 vaccination data reported to the Centers for Disease Control and Prevention. We classified jurisdictions (50 states and the District of Columbia) into quartiles ranging from high to low first-dose vaccination coverage among people aged ≥12 years as of June 30, 2021. We calculated first-dose vaccination coverage as of June 30 and October 31, 2021, and stratified coverage by quartile, age (12-17, 18-64, ≥65 years), and sex. We assessed dose completion among those who initiated a 2-dose vaccine series. Results: Of 51 jurisdictions, 15 reached at least 70% vaccination coverage before the Delta variant surge (ie, as of June 30, 2021), while 35 reached that goal as of October 31, 2021. Jurisdictions in the lowest quartile of vaccination coverage (44.9%-54.9%) had the greatest absolute (9.7%-17.9%) and relative (18.1%-39.8%) percentage increase in vaccination coverage during July 1–October 31, 2021. Of those who received the first dose during this period across all jurisdictions, nearly 1 in 5 missed the second dose. Conclusions: Although COVID-19 vaccination initiation increased during July 1–October 31, 2021, in jurisdictions in the lowest quartile of vaccination coverage, coverage remained below that of jurisdictions in the highest quartile of vaccination coverage before the Delta variant surge. Efforts are needed to improve access to and increase confidence in COVID-19 vaccines, especially in low-coverage areas. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Booster COVID-19 Vaccinations Among Persons Aged ≥5 Years and Second Booster COVID-19 Vaccinations Among Persons Aged ≥50 Years -- United States, August 13, 2021-August 5, 2022.
- Author
-
Fast, Hannah E., Murthy, Bhavini Patel, Zell, Elizabeth, Lu Meng, Murthy, Neil, Saelee, Ryan, Peng-jun Lu, Yoonjae Kang, Shaw, Lauren, Gibbs-Scharf, Lynn, and Harris, LaTreace
- Subjects
COVID-19 vaccines ,BOOSTER vaccines ,OLDER people ,COVID-19 - Published
- 2022
- Full Text
- View/download PDF
25. Using a Cloud-Based Machine Learning Classification Tree Analysis to Understand the Demographic Characteristics Associated With COVID-19 Booster Vaccination Among Adults in the United States.
- Author
-
Meng, Lu, Fast, Hannah E, Saelee, Ryan, Zell, Elizabeth, Murthy, Bhavini Patel, Murthy, Neil Chandra, Lu, Peng-Jun, Shaw, Lauren, Harris, LaTreace, Gibbs-Scharf, Lynn, and Chorba, Terence
- Abstract
A tree model identified adults age ≤34 years, Johnson & Johnson primary series recipients, people from racial/ethnic minority groups, residents of nonlarge metro areas, and those living in socially vulnerable communities in the South as less likely to be boosted. These findings can guide clinical/public health outreach toward specific subpopulations. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. Factors Associated with Delayed or Missed Second-Dose mRNA COVID-19 Vaccination among Persons >12 Years of Age, United States.
- Author
-
Lu Meng, Murthy, Neil Chandra, Murthy, Bhavini Patel, Zell, Elizabeth, Ryan Saelee, Irving, Megan, Fast, Hannah E., Roman, Patricia Castro, Schiller, Adam, Shaw, Lauren, Black, Carla L., Gibbs-Scharf, Lynn, Harris, LaTreace, and Chorba, Terence
- Abstract
To identify demographic factors associated with delaying or not receiving a second dose of the 2-dose primary mRNA COVID-19 vaccine series, we matched 323 million single Pfizer-BioNTech (https://www.pfizer.com) and Moderna (https://www.modernatx.com) COVID-19 vaccine administration records from 2021 and determined whether second doses were delayed or missed. We used 2 sets of logistic regression models to examine associated factors. Overall, 87.3% of recipients received a timely second dose (≤42 days between first and second dose), 3.4% received a delayed second dose (>42 days between first and second dose), and 9.4% missed the second dose. Persons more likely to have delayed or missed the second dose belonged to several racial/ethnic minority groups, were 18-39 years of age, lived in more socially vulnerable areas, and lived in regions other than the northeastern United States. Logistic regression models identified specific subgroups for providing outreach and encouragement to receive subsequent doses on time. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. Recommended Adult Immunization Schedule, United States, 2022.
- Author
-
Murthy, Neil, Wodi, A. Patricia, Bernstein, Henry, Ault, Kevin A., Romero, José R., Cohn, Amanda, Atmar, Robert L., Bahta, Lynn, Bell, Beth P., Cineas, Sybil, Frey, Sharon E., Hunter, Paul, Lee, Grace M., McNally, Veronica V., Poehling, Katherine A., Sánchez, Pablo J., Szilagyi, Peter, Talbot, Helen Keipp, Coles, Sarah, and Debiec, Katherine
- Subjects
- *
IMMUNIZATION , *ADULTS , *SCHEDULING , *VACCINATION - Abstract
This article provides immunization recommendations from the Advisory Committee on Immunization Practices (ACIP) for adults aged 19 years or older. The purpose of the immunization schedule is to consolidate and summarize updates to ACIP recommendations on vaccination of adults and to assist providers in implementing current ACIP recommendations. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged ≥65 Years - United States, August 13, 2021-November 19, 2021.
- Author
-
Fast, Hannah E., Zell, Elizabeth, Patel Murthy, Bhavini, Murthy, Neil, Lu Meng, Gibbs Scharf, Lynn, Black, Carla L., Shaw, Lauren, Chorba, Terence, Harris, LaTreace Q., Murthy, Bhavini Patel, Meng, Lu, and Scharf, Lynn Gibbs
- Abstract
Vaccination against SARS-CoV-2 (the virus that causes COVID-19) is highly effective at preventing hospitalization due to SARS-CoV-2 infection and booster and additional primary dose COVID-19 vaccinations increase protection (1-3). During August-November 2021, a series of Emergency Use Authorizations and recommendations, including those for an additional primary dose for immunocompromised persons and a booster dose for persons aged ≥18 years, were approved because of reduced immunogenicity in immunocompromised persons, waning vaccine effectiveness over time, and the introduction of the highly transmissible B.1.617.2 (Delta) variant (4,5). Adults aged ≥65 years are at increased risk for COVID-19-associated hospitalization and death and were one of the populations first recommended a booster dose in the U.S. (5,6). Data on COVID-19 vaccinations reported to CDC from 50 states, the District of Columbia (DC), and eight territories and freely associated states were analyzed to ascertain coverage with booster or additional primary doses among adults aged ≥65 years. During August 13-November 19, 2021, 18.7 million persons aged ≥65 years received a booster or additional primary dose of COVID-19 vaccine, constituting 44.1% of 42.5 million eligible* persons in this age group who previously completed a primary vaccination series.† Coverage was similar by sex and age group, but varied by primary series vaccine product and race and ethnicity, ranging from 30.3% among non-Hispanic American Indian or Alaska Native persons to 50.5% among non-Hispanic multiple/other race persons. Strategic efforts are needed to encourage eligible persons aged ≥18 years, especially those aged ≥65 years and those who are immunocompromised, to receive a booster and/or additional primary dose to ensure maximal protection against COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. The 6 E Framework of Public Health Preparedness for Mass Gatherings—Lessons Learned From Super Bowl LIII, Fulton County, Georgia, 2019.
- Author
-
Murthy, Neil C., Holland, David P., Chamberlain, Allison T., Smith, Sasha, Callahan, John, and Smith, Wendy
- Published
- 2021
- Full Text
- View/download PDF
30. Telltale 'bathtub rings' reveal ancient rainfall
- Author
-
Murthy, Neil
- Subjects
Tufa -- Observations ,Precipitation variability -- Research ,Meteorological research ,Environmental issues ,Earth sciences - Abstract
In a landscape that could almost have been imaged by Mars rovers, Christine Chen examines stony deposits called tufas along the now dried-up shoreline of an ancient lake high atop [...]
- Published
- 2016
31. Tetanus, Diphtheria, and Acellular Pertussis and Influenza Vaccinations among Women With a Live Birth, Internet Panel Survey, 2017-2018.
- Author
-
Murthy, Neil Chandra, Black, Carla, Kahn, Katherine E, Ding, Helen, Ball, Sarah, Fink, Rebecca V, Devlin, Rebecca, D'Angelo, Denise, and Fiebelkorn, Amy Parker
- Subjects
PREVENTIVE medicine ,MORTALITY prevention ,ATTITUDE (Psychology) ,DPT vaccines ,HEALTH attitudes ,INFANT health services ,INFLUENZA vaccines ,EVALUATION of medical care ,SURVEYS ,VACCINATION ,HEALTH literacy ,PREGNANCY - Abstract
Objectives: Pregnant women are at increased risk of complications from influenza, and infants are at increased risk of pertussis. Maternal influenza and Tdap (tetanus, diphtheria, and acellular pertussis) vaccination can reduce risk of these infections and related complications. Our objective was to estimate vaccination coverage with influenza and Tdap vaccines during pregnancy among women with a recent live birth. Methods: An opt-in Internet panel survey was conducted from March 28 to April 10, 2018 among pregnant and recently pregnant women. Respondents with a live birth from August 1, 2017 through the date in which the participant completed the survey were included in the analysis. Receipt of influenza vaccination since July 1, 2017 and Tdap vaccination during pregnancy were assessed by sociodemographic characteristics, receipt of a health care provider (HCP) recommendation and/or offer of vaccination, and vaccination-related knowledge, attitudes, and beliefs. Results: Less than a third (30.3%) of women with a live birth were unvaccinated during their pregnancy with both Tdap and influenza vaccines. Almost a third (32.8%) of the women reported being vaccinated with both vaccines. The majority (73.0%) of women reported receiving an HCP recommendation for both vaccines, and 54.2% of women were offered both vaccines by an HCP. Reasons for nonvaccination included negative attitudes toward influenza vaccine and lack of awareness about Tdap vaccination during pregnancy. Conclusions: Maternal Tdap and influenza vaccinations can prevent morbidity and mortality among infants and their mothers, yet many pregnant women are unvaccinated with either Tdap or influenza vaccines. Clinic-based education, along with interventions, such as standing orders and provider reminders, are strategies to increase maternal vaccination. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
32. Cost-effectiveness of adult vaccinations: A systematic review.
- Author
-
Leidner, Andrew J., Murthy, Neil, Chesson, Harrell W., Biggerstaff, Matthew, Stoecker, Charles, Harris, Aaron M., Acosta, Anna, Dooling, Kathleen, and Bridges, Carolyn B.
- Subjects
- *
COST effectiveness , *PNEUMOCOCCAL vaccines , *MEDICAL economics , *TARGETED drug delivery , *META-analysis - Abstract
Highlights • Published studies report favorable cost-effectiveness profiles for adult vaccinations. • Some influenza, pneumococcal, and Td/Tdap evaluations report cost-savings. • Adult vaccines can prevent substantial morbidity, disability and death. Abstract Background Coverage levels for many recommended adult vaccinations are low. The cost-effectiveness research literature on adult vaccinations has not been synthesized in recent years, which may contribute to low awareness of the value of adult vaccinations and to their under-utilization. We assessed research literature since 1980 to summarize economic evidence for adult vaccinations included on the adult immunization schedule. Methods We searched PubMed, EMBASE, EconLit, and Cochrane Library from 1980 to 2016 and identified economic evaluation or cost-effectiveness analysis for vaccinations targeting persons aged ≥18 years in the U.S. or Canada. After excluding records based on title and abstract reviews, the remaining publications had a full-text review from two independent reviewers, who extracted economic values that compared vaccination to "no vaccination" scenarios. Results The systematic searches yielded 1688 publications. After removing duplicates, off-topic publications, and publications without a "no vaccination" comparison, 78 publications were included in the final analysis (influenza = 25, pneumococcal = 18, human papillomavirus = 9, herpes zoster = 7, tetanus-diphtheria-pertussis = 9, hepatitis B = 9, and multiple vaccines = 1). Among outcomes assessing age-based vaccinations, the percent indicating cost-savings was 56% for influenza, 31% for pneumococcal, and 23% for tetanus-diphtheria-pertussis vaccinations. Among age-based vaccination outcomes reporting $/QALY, the percent of outcomes indicating a cost per QALY of ≤$100,000 was 100% for influenza, 100% for pneumococcal, 69% for human papillomavirus, 71% for herpes zoster, and 50% for tetanus-diphtheria-pertussis vaccinations. Conclusions The majority of published studies report favorable cost-effectiveness profiles for adult vaccinations, which supports efforts to improve the implementation of adult vaccination recommendations. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
33. Key Elements for Conducting Vaccination Exercises for Pandemic Influenza Preparedness.
- Author
-
Lehnert, Jonathan D., Moulia, Danielle L., Murthy, Neil C., Fiebelkorn, Amy Parker, Vagi, Sara J., Dopson, Stephanie A., and Graitcer, Samuel B.
- Subjects
INFLUENZA vaccines ,PANDEMICS ,PUBLIC health administration ,BEST practices ,VACCINATION centers ,CLINICS ,EMERGENCY management ,PREVENTION of epidemics ,POLICY sciences ,HEALTH services accessibility ,INFLUENZA ,PUBLIC health ,PSYCHOLOGY - Abstract
The article discusses what the authors refer to as the key elements that are needed to conduct vaccination exercises as part of the U.S. Centers for Disease Control and Prevention's (CDC's) Public Health Emergency Preparedness (PHEP) program, and it mentions pandemic influenza-related preparedness and the CDC's "Checklist of Best Practices for Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations." Vaccine handling and storage guidelines are also addressed.
- Published
- 2018
- Full Text
- View/download PDF
34. Notes from the Field: Absence of Asymptomatic Mumps Virus Shedding Among Vaccinated College Students During a Mumps Outbreak - Washington, February-June 2017.
- Author
-
Bonwitt, Jesse, Kawakami, Vance, Wharton, Adam, Burke, Rachel M, Murthy, Neil, Lee, Adria, Dell, BreeAnna, Kay, Meagan, Duchin, Jeff, Hickman, Carole, McNall, Rebecca J, Rota, Paul A, Patel, Manisha, Lindquist, Scott, DeBolt, Chas, and Routh, Janell
- Published
- 2017
- Full Text
- View/download PDF
35. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2024.
- Author
-
Murthy N, Wodi AP, McNally VV, Daley MF, and Cineas S
- Subjects
- Adult, Humans, Centers for Disease Control and Prevention, U.S., Immunization Schedule, United States, Vaccination, Advisory Committees, Immunization
- Abstract
At its October 2023 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, 2024. The adult immunization schedule, which can be found on the CDC immunization schedule website (https://www.cdc.gov/vaccines/schedules), is published annually to consolidate and summarize updates to ACIP recommendations on the vaccination of adults and to assist health care providers in implementing current ACIP recommendations. The 2024 immunization schedule includes several changes to the cover page, tables, notes, and appendix from the 2023 immunization schedule.
† In addition, the 2024 adult immunization schedule includes a new addendum section that summarizes new or updated ACIP recommendations that will occur before the next annual update to the adult immunization schedule. Health care providers are advised to use the cover page, tables, notes, appendix, and addendum together to determine recommended vaccinations for patient populations., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Veronica V. McNally reports that she is the president of the Franny Strong Foundation, and that she received an honorarium for presenting to the Michigan Vaccine Project on May 23, 2023. No other potential conflicts of interest were disclosed.- Published
- 2024
- Full Text
- View/download PDF
36. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2024.
- Author
-
Wodi AP, Murthy N, McNally VV, Daley MF, and Cineas S
- Subjects
- Adolescent, Child, Humans, Infant, Centers for Disease Control and Prevention, U.S., Immunization Schedule, United States, Vaccination, Advisory Committees, Immunization
- Abstract
At its October 2023 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024. The child and adolescent immunization schedule, which can be found on the CDC immunization schedule website (https://www.cdc.gov/vaccines/schedules), is published annually to consolidate and summarize updates to ACIP recommendations on the vaccination of children and adolescents and to assist health care providers in implementing current ACIP recommendations. The 2024 immunization schedule includes several changes to the cover page, tables, notes, and appendix from the 2023 immunization schedule.
† In addition, the 2024 child and adolescent immunization schedule includes a new addendum section to summarize new or updated ACIP recommendations that will occur before the next annual update to the child and adolescent immunization schedule. Health care providers are advised to use the cover page, tables, notes, appendix, and addendum together to identify the recommended immunizations for patient populations., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Veronica V. McNally reports that she is the president of the Franny Strong Foundation and that she received an honorarium for presenting to the Michigan Vaccine Project on May 23, 2023. No other potential conflicts of interest were disclosed.- Published
- 2024
- Full Text
- View/download PDF
37. COVID-19 Vaccination Coverage and Demographic Characteristics of Infants and Children Aged 6 Months-4 Years - United States, June 20-December 31, 2022.
- Author
-
Murthy BP, Fast HE, Zell E, Murthy N, Meng L, Shaw L, Vogt T, Chatham-Stephens K, Santibanez TA, Gibbs-Scharf L, and Harris LQ
- Subjects
- Infant, United States epidemiology, Humans, Child, Adolescent, Aged, Vaccination Coverage, 2019-nCoV Vaccine mRNA-1273, BNT162 Vaccine, Vaccination, District of Columbia, Demography, COVID-19 Vaccines, COVID-19 epidemiology, COVID-19 prevention & control
- Abstract
Although severe COVID-19 illness and hospitalization are more common among older adults, children can also be affected (1). More than 3 million cases of COVID-19 had been reported among infants and children aged <5 years (children) as of December 2, 2022 (2). One in four children hospitalized with COVID-19 required intensive care; 21.2% of cases of COVID-19-related multisystem inflammatory syndrome in children (MIS-C) occurred among children aged 1-4 years, and 3.2% of MIS-C cases occurred among infants aged <1 year (1,3). On June 17, 2022, the Food and Drug Administration issued an Emergency Use Authorization (EUA) of the Moderna COVID-19 vaccine for children aged 6 months-5 years and the Pfizer-BioNTech COVID-19 vaccine for children aged 6 months-4 years. To assess COVID-19 vaccination coverage among children aged 6 months-4 years in the United States, coverage with ≥1 dose* and completion of the 2-dose or 3-dose primary vaccination series
† were assessed using vaccine administration data for the 50 U.S. states and District of Columbia submitted from June 20 (after COVID-19 vaccine was first authorized for this age group) through December 31, 2022. As of December 31, 2022, ≥1-dose COVID-19 vaccination coverage among children aged 6 months-4 years was 10.1% and was 5.1% for series completion. Coverage with ≥1 dose varied by jurisdiction (range = 2.1% [Mississippi] to 36.1% [District of Columbia]) as did coverage with a completed series (range = 0.7% [Mississippi] to 21.4% [District of Columbia]), respectively. By age group, 9.7 % of children aged 6-23 months and 10.2% of children aged 2-4 years received ≥1 dose; 4.5% of children aged 6-23 months and 5.4% of children aged 2-4 years completed the vaccination series. Among children aged 6 months-4 years, ≥1-dose COVID-19 vaccination coverage was lower in rural counties (3.4%) than in urban counties (10.5%). Among children aged 6 months-4 years who received at least the first dose, only 7.0% were non-Hispanic Black or African American (Black), and 19.9% were Hispanic or Latino (Hispanic), although these demographic groups constitute 13.9% and 25.9% of the population, respectively (4). COVID-19 vaccination coverage among children aged 6 months-4 years is substantially lower than that among older children (5). Efforts are needed to improve vaccination coverage among children aged 6 months-4 years to reduce COVID-19-associated morbidity and mortality., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.- Published
- 2023
- Full Text
- View/download PDF
38. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2023.
- Author
-
Murthy N, Wodi AP, McNally V, Cineas S, and Ault K
- Subjects
- Adult, Humans, Centers for Disease Control and Prevention, U.S., Immunization Schedule, United States, Vaccination, Advisory Committees, Immunization
- Abstract
At its October 2022 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, 2023. The 2023 adult immunization schedule summarizes ACIP recommendations, including several changes to the cover page, tables, notes, and appendix from the 2022 immunization schedule.
† This schedule can be found on the CDC immunization schedule website (https://www.cdc.gov/vaccines/schedules). Health care providers are advised to use the cover page, tables, notes, and appendix together to determine recommended vaccinations for patient populations. This adult immunization schedule is recommended by ACIP (https://www.cdc.gov/vaccines/acip) and approved by CDC (https://www.cdc.gov), the American College of Physicians (https://www.acponline.org), the American Academy of Family Physicians (https://www.aafp.org), the American College of Obstetricians and Gynecologists (https://www.acog.org), the American College of Nurse-Midwives (https://www.midwife.org), the American Academy of Physician Associates (https://www.aapa.org), the American Pharmacists Association (https://www.pharmacist.com), and the Society for Healthcare Epidemiology of America (https://shea-online.org)., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Veronica McNally reports that she is the president of the Franny Strong Foundation. Kevin Ault reports having received consulting fees from PathoVax, serving as a volunteer on the medical advisory board of Family Fighting Flu, and as a committee member of the American College of Obstetricians and Gynecologists. No other potential conflicts of interest were disclosed.- Published
- 2023
- Full Text
- View/download PDF
39. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2023.
- Author
-
Wodi AP, Murthy N, McNally V, Cineas S, and Ault K
- Subjects
- Adolescent, Child, Humans, Centers for Disease Control and Prevention, U.S., Immunization Schedule, United States, Vaccination, Advisory Committees, Immunization
- Abstract
At its October 2022 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2023. The 2023 child and adolescent immunization schedule, available on the CDC immunization schedule website (https://www.cdc.gov/vaccines/schedules), summarizes ACIP recommendations, including several changes from the 2022 immunization schedule
† on the cover page, tables, notes, and appendix. Health care providers are advised to use the tables, notes, and appendix together to determine recommended vaccinations for patient populations. This immunization schedule is recommended by ACIP (https://www.cdc.gov/vaccines/acip) and approved by CDC (https://www.cdc.gov), the American Academy of Pediatrics (https://www.aap.org), the American Academy of Family Physicians (https://www.aafp.org), the American College of Obstetricians and Gynecologists (http://www.acog.org), the American College of Nurse-Midwives (https://www.midwife.org), the American Academy of Physician Associates (https://www.aapa.org), and the National Association of Pediatric Nurse Practitioners (https://www.napnap.org)., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Veronica McNally reports that she is the president of the Franny Strong Foundation. Kevin Ault reports having received consulting fees from PathoVax, serving as a volunteer on the medical advisory board of Family Fighting Flu, and as a committee member of the American College of Obstetricians and Gynecologists. No other potential conflicts of interest were disclosed.- Published
- 2023
- Full Text
- View/download PDF
40. COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022.
- Author
-
Havers FP, Pham H, Taylor CA, Whitaker M, Patel K, Anglin O, Kambhampati AK, Milucky J, Zell E, Moline HL, Chai SJ, Kirley PD, Alden NB, Armistead I, Yousey-Hindes K, Meek J, Openo KP, Anderson EJ, Reeg L, Kohrman A, Lynfield R, Como-Sabetti K, Davis EM, Cline C, Muse A, Barney G, Bushey S, Felsen CB, Billing LM, Shiltz E, Sutton M, Abdullah N, Talbot HK, Schaffner W, Hill M, George A, Hall AJ, Bialek SR, Murthy NC, Murthy BP, and McMorrow M
- Subjects
- Adult, Aged, COVID-19 Vaccines, Cross-Sectional Studies, Hospitalization, Humans, SARS-CoV-2, COVID-19 epidemiology, COVID-19 prevention & control, Influenza Vaccines
- Abstract
Importance: Understanding risk factors for hospitalization in vaccinated persons and the association of COVID-19 vaccines with hospitalization rates is critical for public health efforts to control COVID-19., Objective: To determine characteristics of COVID-19-associated hospitalizations among vaccinated persons and comparative hospitalization rates in unvaccinated and vaccinated persons., Design, Setting, and Participants: From January 1, 2021, to April 30, 2022, patients 18 years or older with laboratory-confirmed SARS-CoV-2 infection were identified from more than 250 hospitals in the population-based COVID-19-Associated Hospitalization Surveillance Network. State immunization information system data were linked to cases, and the vaccination coverage data of the defined catchment population were used to compare hospitalization rates in unvaccinated and vaccinated individuals. Vaccinated and unvaccinated patient characteristics were compared in a representative sample with detailed medical record review; unweighted case counts and weighted percentages were calculated., Exposures: Laboratory-confirmed COVID-19-associated hospitalization, defined as a positive SARS-CoV-2 test result within 14 days before or during hospitalization., Main Outcomes and Measures: COVID-19-associated hospitalization rates among vaccinated vs unvaccinated persons and factors associated with COVID-19-associated hospitalization in vaccinated persons were assessed., Results: Using representative data from 192 509 hospitalizations (see Table 1 for demographic information), monthly COVID-19-associated hospitalization rates ranged from 3.5 times to 17.7 times higher in unvaccinated persons than vaccinated persons regardless of booster dose status. From January to April 2022, when the Omicron variant was predominant, hospitalization rates were 10.5 times higher in unvaccinated persons and 2.5 times higher in vaccinated persons with no booster dose, respectively, compared with those who had received a booster dose. Among sampled cases, vaccinated hospitalized patients with COVID-19 were older than those who were unvaccinated (median [IQR] age, 70 [58-80] years vs 58 [46-70] years, respectively; P < .001) and more likely to have 3 or more underlying medical conditions (1926 [77.8%] vs 4124 [51.6%], respectively; P < .001)., Conclusions and Relevance: In this cross-sectional study of US adults hospitalized with COVID-19, unvaccinated adults were more likely to be hospitalized compared with vaccinated adults; hospitalization rates were lowest in those who had received a booster dose. Hospitalized vaccinated persons were older and more likely to have 3 or more underlying medical conditions and be long-term care facility residents compared with hospitalized unvaccinated persons. The study results suggest that clinicians and public health practitioners should continue to promote vaccination with all recommended doses for eligible persons.
- Published
- 2022
- Full Text
- View/download PDF
41. Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties - United States, December 14, 2020-January 31, 2022.
- Author
-
Saelee R, Zell E, Murthy BP, Castro-Roman P, Fast H, Meng L, Shaw L, Gibbs-Scharf L, Chorba T, Harris LQ, and Murthy N
- Subjects
- Adolescent, Adult, Aged, Child, Female, Humans, Male, Middle Aged, Rural Population, United States epidemiology, Urban Population, COVID-19 Vaccines administration & dosage, Healthcare Disparities, Vaccination Coverage
- Abstract
Higher COVID-19 incidence and mortality rates in rural than in urban areas are well documented (1). These disparities persisted during the B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant surges during late 2021 and early 2022 (1,2). Rural populations tend to be older (aged ≥65 years) and uninsured and are more likely to have underlying medical conditions and live farther from facilities that provide tertiary medical care, placing them at higher risk for adverse COVID-19 outcomes (2). To better understand COVID-19 vaccination disparities between urban and rural populations, CDC analyzed county-level vaccine administration data among persons aged ≥5 years who received their first dose of either the BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccine or a single dose of the Ad.26.COV2.S (Janssen [Johnson & Johnson]) COVID-19 vaccine during December 14, 2020-January 31, 2022, in 50 states and the District of Columbia (DC). COVID-19 vaccination coverage with ≥1 doses in rural areas (58.5%) was lower than that in urban counties (75.4%) overall, with similar patterns across age groups and sex. Coverage with ≥1 doses varied among states: 46 states had higher coverage in urban than in rural counties, one had higher coverage in rural than in urban counties. Three states and DC had no rural counties; thus, urban-rural differences could not be assessed. COVID-19 vaccine primary series completion was higher in urban than in rural counties. However, receipt of booster or additional doses among primary series recipients was similarly low between urban and rural counties. Compared with estimates from a previous study of vaccine coverage among adults aged ≥18 years during December 14, 2020-April 10, 2021, these urban-rural disparities among those now eligible for vaccination (aged ≥5 years) have increased more than twofold through January 2022, despite increased availability and access to COVID-19 vaccines. Addressing barriers to vaccination in rural areas is critical to achieving vaccine equity, reducing disparities, and decreasing COVID-19-related illness and death in the United States (2)., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
- Published
- 2022
- Full Text
- View/download PDF
42. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2022.
- Author
-
Murthy N, Wodi AP, Bernstein H, McNally V, Cineas S, and Ault K
- Subjects
- Adult, Aged, Centers for Disease Control and Prevention, U.S., Humans, Middle Aged, United States, Advisory Committees, Health Planning Guidelines, Immunization Schedule
- Abstract
At its November 2021 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, 2022. The 2022 adult immunization schedule summarizes ACIP recommendations, including several changes to the cover page, tables, and notes from the 2021 immunization schedule.
† In addition, the 2022 adult immunization schedule provides an appendix that lists the contraindications to and precautions for all routinely recommended vaccines in the schedule. This schedule can be found on the CDC immunization schedule website (https://www.cdc.gov/vaccines/schedules). Health care providers are advised to use the cover page, tables, notes, and appendix together. This adult immunization schedule is recommended by ACIP (https://www.cdc.gov/vaccines/acip) and approved by CDC (https://www.cdc.gov), the American College of Physicians (https://www.acponline.org), the American Academy of Family Physicians (https://www.aafp.org), the American College of Obstetricians and Gynecologists (https://www.acog.org), the American College of Nurse-Midwives (https://www.midwife.org), the American Academy of Physician Associates (https://www.aapa.org), and the Society for Healthcare Epidemiology of America (https://www.shea-online.org)., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Henry Bernstein reports that he is the editor of Current Opinion in Pediatrics Office Pediatrics Series and received a presentation honorarium from the Florida chapter of American Academy of Pediatrics. Veronica McNally reports that she is the president of the Franny Strong Foundation. Kevin Ault reports having received a grant from the National Cancer Institute, consulting fees from PathoVax, and payments supporting attending meetings and/or travel from the American College of Obstetricians and Gynecologists. In addition, Kevin Ault reports that he serves as a volunteer on the medical advisory board of Family Fighting Flu, and as a member of the infectious disease working group for the American College of Obstetricians and Gynecologists. No other potential conflicts of interest were disclosed.- Published
- 2022
- Full Text
- View/download PDF
43. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2022.
- Author
-
Wodi AP, Murthy N, Bernstein H, McNally V, Cineas S, and Ault K
- Subjects
- Adolescent, Centers for Disease Control and Prevention, U.S., Child, Child, Preschool, Humans, Infant, United States, Advisory Committees, Health Planning Guidelines, Immunization Schedule
- Abstract
At its November 2021 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger-United States, 2022. The 2022 child and adolescent immunization schedule, found on the CDC immunization schedule website (https://www.cdc.gov/vaccines/schedules), summarizes ACIP recommendations, including several changes from the 2021 immunization schedule
† on the cover page, tables, and notes. The 2022 child and adolescent schedule also includes a newly created appendix that lists the contraindications and precautions for all vaccine types in the schedule. Health care providers are advised to use the tables, notes, and appendix together. This immunization schedule is recommended by ACIP (https://www.cdc.gov/vaccines/acip) and approved by CDC (https://www.cdc.gov), the American Academy of Pediatrics (https://www.aap.org), the American Academy of Family Physicians (https://www.aafp.org), the American College of Obstetricians and Gynecologists (http://www.acog.org), the American College of Nurse-Midwives (https://www.midwife.org), the American Academy of Physician Associates (https://www.aapa.org), and the National Association of Pediatric Nurse Practitioners (https://www.napnap.org)., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Henry Bernstein reports that he is the editor of Current Opinion in Pediatrics Office Pediatrics Series and received a presentation honorarium from the Florida chapter of American Academy of Pediatrics. Veronica McNally reports that she is the president of the Franny Strong Foundation. Kevin Ault reports having received a grant from the National Cancer Institute, consulting fees from PathoVax, and payments supporting attending meetings and/or travel from the American College of Obstetricians and Gynecologists. In addition, Kevin Ault reports that he serves as a volunteer on the medical advisory board of Family Fighting Flu, and as a member of the infectious disease working group for the American College of Obstetricians and Gynecologists. No other potential conflicts of interest were disclosed.- Published
- 2022
- Full Text
- View/download PDF
44. COVID-19 Vaccination Coverage Among Adolescents Aged 12-17 Years - United States, December 14, 2020-July 31, 2021.
- Author
-
Murthy BP, Zell E, Saelee R, Murthy N, Meng L, Meador S, Reed K, Shaw L, Gibbs-Scharf L, McNaghten AD, Patel A, Stokley S, Flores S, Yoder JS, Black CL, and Harris LQ
- Subjects
- Adolescent, COVID-19 epidemiology, Child, Female, Humans, Male, United States epidemiology, COVID-19 prevention & control, COVID-19 Vaccines administration & dosage, Vaccination Coverage statistics & numerical data
- Abstract
Although severe COVID-19 illness and hospitalization are more common among adults, these outcomes can occur in adolescents (1). Nearly one third of adolescents aged 12-17 years hospitalized with COVID-19 during March 2020-April 2021 required intensive care, and 5% of those hospitalized required endotracheal intubation and mechanical ventilation (2). On December 11, 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine for adolescents aged 16-17 years; on May 10, 2021, the EUA was expanded to include adolescents aged 12-15 years; and on August 23, 2021, FDA granted approval of the vaccine for persons aged ≥16 years. To assess progress in adolescent COVID-19 vaccination in the United States, CDC assessed coverage with ≥1 dose* and completion of the 2-dose vaccination series
† among adolescents aged 12-17 years using vaccine administration data for 49 U.S. states (all except Idaho) and the District of Columbia (DC) during December 14, 2020-July 31, 2021. As of July 31, 2021, COVID-19 vaccination coverage among U.S. adolescents aged 12-17 years was 42.4% for ≥1 dose and 31.9% for series completion. Vaccination coverage with ≥1 dose varied by state (range = 20.2% [Mississippi] to 70.1% [Vermont]) and for series completion (range = 10.7% [Mississippi] to 60.3% [Vermont]). By age group, 36.0%, 40.9%, and 50.6% of adolescents aged 12-13, 14-15, and 16-17 years, respectively, received ≥1 dose; 25.4%, 30.5%, and 40.3%, respectively, completed the vaccine series. Improving vaccination coverage and implementing COVID-19 prevention strategies are crucial to reduce COVID-19-associated morbidity and mortality among adolescents and to facilitate safer reopening of schools for in-person learning., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.- Published
- 2021
- Full Text
- View/download PDF
45. Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties - United States, December 14, 2020-April 10, 2021.
- Author
-
Murthy BP, Sterrett N, Weller D, Zell E, Reynolds L, Toblin RL, Murthy N, Kriss J, Rose C, Cadwell B, Wang A, Ritchey MD, Gibbs-Scharf L, Qualters JR, Shaw L, Brookmeyer KA, Clayton H, Eke P, Adams L, Zajac J, Patel A, Fox K, Williams C, Stokley S, Flores S, Barbour KE, and Harris LQ
- Subjects
- Adolescent, Adult, Aged, COVID-19 epidemiology, COVID-19 prevention & control, Female, Humans, Male, Middle Aged, United States epidemiology, Young Adult, COVID-19 Vaccines administration & dosage, Healthcare Disparities statistics & numerical data, Rural Population statistics & numerical data, Urban Population statistics & numerical data, Vaccination Coverage statistics & numerical data
- Abstract
Approximately 60 million persons in the United States live in rural counties, representing almost one fifth (19.3%) of the population.* In September 2020, COVID-19 incidence (cases per 100,000 population) in rural counties surpassed that in urban counties (1). Rural communities often have a higher proportion of residents who lack health insurance, live with comorbidities or disabilities, are aged ≥65 years, and have limited access to health care facilities with intensive care capabilities, which places these residents at increased risk for COVID-19-associated morbidity and mortality (2,3). To better understand COVID-19 vaccination disparities across the urban-rural continuum, CDC analyzed county-level vaccine administration data among adults aged ≥18 years who received their first dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccine, or a single dose of the Janssen COVID-19 vaccine (Johnson & Johnson) during December 14, 2020-April 10, 2021 in 50 U.S. jurisdictions (49 states and the District of Columbia [DC]). Adult COVID-19 vaccination coverage was lower in rural counties (38.9%) than in urban counties (45.7%) overall and among adults aged 18-64 years (29.1% rural, 37.7% urban), those aged ≥65 years (67.6% rural, 76.1% urban), women (41.7% rural, 48.4% urban), and men (35.3% rural, 41.9% urban). Vaccination coverage varied among jurisdictions: 36 jurisdictions had higher coverage in urban counties, five had higher coverage in rural counties, and five had similar coverage (i.e., within 1%) in urban and rural counties; in four jurisdictions with no rural counties, the urban-rural comparison could not be assessed. A larger proportion of persons in the most rural counties (14.6%) traveled for vaccination to nonadjacent counties (i.e., farther from their county of residence) compared with persons in the most urban counties (10.3%). As availability of COVID-19 vaccines expands, public health practitioners should continue collaborating with health care providers, pharmacies, employers, faith leaders, and other community partners to identify and address barriers to COVID-19 vaccination in rural areas (2)., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
- Published
- 2021
- Full Text
- View/download PDF
46. Vaccination Coverage Among Children Aged 2 Years - U.S. Affiliated Pacific Islands, April-October, 2016.
- Author
-
Tippins A, Murthy N, Meghani M, Solsman A, Apaisam C, Basilius M, Eckert M, Judicpa P, Masunu Y, Pistotnik K, Pedro D, Sasamoto J, and Underwood JM
- Subjects
- Child, Preschool, Diphtheria-Tetanus-Pertussis Vaccine administration & dosage, Female, Hepatitis B Vaccines administration & dosage, Humans, Immunization Schedule, Male, Measles-Mumps-Rubella Vaccine administration & dosage, Medical Records, Pacific Islands, Pneumococcal Vaccines administration & dosage, Rotavirus Vaccines administration & dosage, Vaccination Coverage statistics & numerical data, Vaccines administration & dosage
- Abstract
Vaccine-preventable diseases (VPDs) cause substantial morbidity and mortality in the United States Affiliated Pacific Islands (USAPI).* CDC collaborates with USAPI immunization programs to monitor vaccination coverage. In 2016,
† USAPI immunization programs and CDC piloted a method for estimating up-to-date status among children aged 2 years using medical record abstraction to ascertain regional vaccination coverage. This was the first concurrent assessment of childhood vaccination coverage across five USAPI jurisdictions (American Samoa; Chuuk State, Federated States of Micronesia [FSM]; Commonwealth of the Northern Mariana Islands [CNMI]; Republic of the Marshall Islands [RMI]; and Republic of Palau).§ Differences in vaccination coverage between main and outer islands¶ were assessed for two jurisdictions where data were adequate.** Series coverage in this report includes the following doses of vaccines: ≥4 doses of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP); ≥3 doses of inactivated poliovirus vaccine (IPV); ≥1 dose of measles, mumps, and rubella vaccine (MMR); ≥3 doses of Haemophilus influenzae type B (Hib) vaccine; ≥3 doses of hepatitis B (HepB) vaccine; and ≥4 doses of pneumococcal conjugate vaccine (PCV); i.e., 4:3:1:3:3:4. Coverage with ≥3 doses of rotavirus vaccine was also assessed. Completion of the recommended series of each of these vaccines†† was <90% in all jurisdictions except Palau. Coverage with the full recommended six-vaccine series (4:3:1:3:3:4) ranged from 19.5% (Chuuk) to 69.1% (Palau). In RMI and Chuuk, coverage was lower in the outer islands than in the main islands for most vaccines, with differences ranging from 0.9 to 66.8 percentage points. Medical record abstraction enabled rapid vaccination coverage assessment and timely dissemination of results to guide programmatic decision-making. Effectively monitoring vaccination coverage, coupled with implementation of data-driven interventions, is essential to maintain protection from VPD outbreaks in the region and the mainland United States., Competing Interests: No conflicts of interest were reported.- Published
- 2018
- Full Text
- View/download PDF
47. Progress in Childhood Vaccination Data in Immunization Information Systems - United States, 2013-2016.
- Author
-
Murthy N, Rodgers L, Pabst L, Fiebelkorn AP, and Ng T
- Subjects
- Child, Preschool, Health Care Surveys, Humans, Infant, Program Evaluation, United States, Immunization statistics & numerical data, Immunization Programs, Information Systems trends
- Abstract
In 2016, 55 jurisdictions in 49 states and six cities in the United States* used immunization information systems (IISs) to collect and manage immunization data and support vaccination providers and immunization programs. To monitor progress toward achieving IIS program goals, CDC surveys jurisdictions through an annual self-administered IIS Annual Report (IISAR). Data from the 2013-2016 IISARs were analyzed to assess progress made in four priority areas: 1) data completeness, 2) bidirectional exchange of data with electronic health record systems, 3) clinical decision support for immunizations, and 4) ability to generate childhood vaccination coverage estimates. IIS participation among children aged 4 months through 5 years increased from 90% in 2013 to 94% in 2016, and 33 jurisdictions reported ≥95% of children aged 4 months through 5 years participating in their IIS in 2016. Bidirectional messaging capacity in IISs increased from 25 jurisdictions in 2013 to 37 in 2016. In 2016, nearly all jurisdictions (52 of 55) could provide automated provider-level coverage reports, and 32 jurisdictions reported that their IISs could send vaccine forecasts to providers via Health Level 7 (HL7) messaging, up from 17 in 2013. Incremental progress was made in each area since 2013, but continued effort is needed to implement these critical functionalities among all IISs. Success in these priority areas, as defined by the IIS Functional Standards (1), bolsters clinicians' and public health practitioners' ability to attain high vaccination coverage in pediatric populations, and prepares IISs to develop more advanced functionalities to support state/local immunization services. Success in these priority areas also supports the achievement of federal immunization objectives, including the use of IISs as supplemental sampling frames for vaccination coverage surveys like the National Immunization Survey (NIS)-Child, reducing data collection costs, and supporting increased precision of state-level estimates.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.